drug and hormone therapy

Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found. Women taking palbociclib together with hormone therapy lived seven months longer than those on hormone treatment alone - adding to previous data showing the combination could delay the disease's progression. The drug's benefit was stronger in women who had previously responded to hormone therapy - who lived 10 months longer with the combination